Abbott Laboratories (ABT) Q2 2026 (USD): Adj. EPS 1.31 (exp. 1.28), Revenue 12.6bln (exp. 12.52bln). Raises FY adj. EPS view 5.45-5.60 (exp. 5.49, prev. 5.38-5.58), Reaffirms sales growth view 6.5-7.5%.
#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#ABBOTT LABORATORIES#ABT.US#IMPORTANT#FOREX#EQUITIES#METALS#EU SESSION#US SESSION#HEALTH CARE EQUIPMENT#METALS & MINING#HEALTH CARE EQUIPMENT & SUPPLIES#HEALTH CARE EQUIPMENT & SERVICES (GROUP)#S&P 500 INDEX#ABT#DXY#US EQUITIES